Fernando Lobo

Dr. Fernando Lobo


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FLFernando Lobo
Fernando Lobo
MAMaily Gonzalez Aviles
Maily Gonzalez Aviles
ABAlicia Boto
Alicia Boto
JLJosé Pérez de la Lastra
José Pérez de la Lastra
Peptides with antifungal activity have gained significant attention due to their potential therapeutic applications. In this study, we explore the use of pretrained protein models as feature extractors to develop predictive models for antifungal peptide activity. Various machine learning classifiers were trained and evaluated. Our AFP predictor achieved comparable performance to current state-of-the-art methods. Overall, our study demonstrates the effectiveness of pretrained models for peptide analysis and provides a valuable tool for predicting antifungal peptide activity and potentially other peptide properties.

5 July 2022 in Agronomy
Verified
Journal Article
Open access
PDF file
FLFernando Lobo
Fernando Lobo
ABAlicia Boto
Alicia Boto
Host-defense peptides (HDP) are emerging as promising phytosanitaries due to their potency, low plant, animal and environmental toxicity, and above all, low induction of antimicrobial resistance. These natural compounds, which have been used by animals and plants over millions of years to defend themselves against pathogens, are being discovered by genome mining, and then produced using biofactories. Moreover, truncated or otherwise modified peptides, including ultra-short ones, have been developed to improve their bioactivities and biodistribution, and also to reduce production costs. The synergistic combination of HDP and other antimicrobials, and the development of hybrid molecules have also given promising results. Finally, although their low induction of antimicrobial resistance is a big advantage, cautionary measures for the sustainable use of HDPs, such as the use of precision agriculture tools, were discussed.

Verified
Journal Article
Open access
PDF file
Mario DiazMario Diaz
Mario Diaz
FLFernando Lobo
Fernando Lobo
DHDácil Hernández
Dácil Hernández
ÁAÁngel Amesty
Ángel Amesty
CVCatalina Valdés-Baizabal
Catalina Valdés-Baizabal
FLFernando Lahoz
Fernando Lahoz
Tamoxifen is the most widely used selective modulator of estrogen receptors (SERM) and the first strategy as coadjuvant therapy for the treatment of estrogen-receptor (ER) positive breast cancer worldwide. In spite of such success, tamoxifen is not devoid of undesirable effects, the most life-threatening reported so far affecting uterine tissues. Indeed, tamoxifen treatment is discouraged in women under risk of uterine cancers. Recent molecular design efforts have endeavoured the development of tamoxifen derivatives with antiestrogen properties but lacking agonistic uterine tropism. One of this is FLTX2, formed by the covalent binding of tamoxifen as ER binding core, 7-nitrobenzofurazan (NBD) as the florescent dye, and Rose Bengal (RB) as source for reactive oxygen species. Our analyses demonstrate (1) FLTX2 is endowed with similar antiestrogen potency as tamoxifen and its predecessor FLTX1, (2) shows a strong absorption in the blue spectral range, associated to the NBD moiety, which efficiently transfers the excitation energy to RB through intramolecular FRET mechanism, (3) generates superoxide anions in a concentration- and irradiation time-dependent process, and (4) Induces concentration- and time-dependent MCF7 apoptotic cell death. These properties make FLTX2 a very promising candidate to lead a novel generation of SERMs with the endogenous capacity to promote breast tumour cell death in situ by photosensitization.

14 June 2021
Verified
Conference Paper
Open access
FLFernando Lobo
Fernando Lobo
DMDácil Hernández Mesa
Dácil Hernández Mesa
CSCarlos Javier Saavedra
Carlos Javier Saavedra
ABAlicia Boto
Alicia Boto
FLFernando Lahoz
Fernando Lahoz
Mario DiazMario Diaz
Mario Diaz
Tamoxifen 1 is a selective modulator of estrogen receptors, used in prevention and clinical treatment of breast cancer, but displays some important side-effects, such as an increase in the overt of uterine endometrial cancer. Some years ago we reported a tamoxifen derivative FLTX1 (2) which incorporated a fluorescent NBD group. The pharmacological profile of